CATALOGO DEI PRODOTTI DELLA RICERCA

BONIFACIO, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.642
EU - Europa 4.287
AS - Asia 1.991
OC - Oceania 26
SA - Sud America 21
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 6
Totale 10.983
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.620
CN - Cina 1.533
GB - Regno Unito 1.405
IT - Italia 475
SE - Svezia 470
FR - Francia 409
IE - Irlanda 408
DE - Germania 329
RU - Federazione Russa 320
FI - Finlandia 227
SG - Singapore 163
UA - Ucraina 90
VN - Vietnam 62
HK - Hong Kong 58
IN - India 47
NL - Olanda 42
BE - Belgio 35
KR - Corea 28
AU - Australia 25
JP - Giappone 24
TR - Turchia 23
IR - Iran 17
CA - Canada 16
RO - Romania 12
AT - Austria 10
AR - Argentina 8
CH - Svizzera 8
ES - Italia 8
CZ - Repubblica Ceca 7
PL - Polonia 7
CL - Cile 6
NO - Norvegia 6
GR - Grecia 5
MA - Marocco 5
NP - Nepal 5
BR - Brasile 4
EU - Europa 4
DK - Danimarca 3
ID - Indonesia 3
MX - Messico 3
MY - Malesia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BD - Bangladesh 2
CR - Costa Rica 2
DZ - Algeria 2
HU - Ungheria 2
IQ - Iraq 2
LV - Lettonia 2
PE - Perù 2
PK - Pakistan 2
QA - Qatar 2
SA - Arabia Saudita 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BY - Bielorussia 1
CY - Cipro 1
EE - Estonia 1
GE - Georgia 1
HR - Croazia 1
IL - Israele 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MK - Macedonia 1
MU - Mauritius 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SM - San Marino 1
TH - Thailandia 1
UG - Uganda 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 10.983
Salva come PNG Salva come JPEG
Città #
Southend 1.303
Chandler 974
Woodbridge 505
Dublin 406
Beijing 400
Ann Arbor 329
Jacksonville 266
Houston 255
Ashburn 238
Wilmington 194
Lawrence 173
Princeton 173
Verona 140
Jinan 131
Nanjing 120
Shenyang 120
New York 119
Singapore 94
Redmond 88
Sindelfingen 79
Hebei 76
Hong Kong 57
Helsinki 56
Tianjin 52
Falls Church 46
Zhengzhou 45
Nanchang 44
Ningbo 44
Fuzhou 43
Redwood City 43
Taizhou 43
Changsha 42
Dong Ket 40
Bologna 38
Haikou 37
Hangzhou 36
Brussels 35
Milan 32
Guangzhou 31
Norwalk 30
Seattle 29
Kent 27
Jiaxing 26
Seoul 26
Taiyuan 23
Groningen 22
Los Angeles 20
Tokyo 19
Chicago 18
Dearborn 16
Provo 16
Rome 16
Düsseldorf 15
Boardman 13
Lanzhou 13
Washington 12
Chengdu 11
Lancaster 11
San Francisco 11
Kochi 10
Perth 10
Brescia 8
Fremont 8
Timisoara 8
Vienna 8
Amsterdam 7
Fairfield 7
Leawood 7
Riva 7
Ardabil 6
Clearwater 6
Costa Mesa 6
Nürnberg 6
Vancouver 6
Buffalo 5
Florence 5
Parsa 5
San Jose 5
Santa Clara 5
Shanghai 5
Tehran 5
Andover 4
Augusta 4
Bergamo 4
Cambridge 4
Hefei 4
Hyderabad 4
Melbourne 4
Mountain View 4
Newbury Park 4
Nuremberg 4
Oslo 4
Paris 4
Putian 4
Ravenna 4
Toronto 4
Trento 4
Athens 3
Bareggio 3
Brno 3
Totale 7.539
Salva come PNG Salva come JPEG
Nome #
Epidemiology of mastocytosis in adults based on a multidisciplinary diagnostic approach. 219
Notch singalling inhibition as a multi-target therapy to overcome bone marrow microenvironment-mediated drug resistance in AML 131
Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia 123
Role of GSK-3 signalling in non-promyelocitic acute myeloid leukemia (AML) cell response to chemotherapy 122
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 121
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 118
α-bisabolol is an effective proapoptotic agent against BCR-ABL+ cells in synergism with Imatinib and Nilotinib 116
BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL) 114
Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis 114
Clonal mast cell disorders limited to bone marrow: not a negligible disease. 113
Value of flow cytometry in the diagnosis of indolent systemic mastocytosis. 112
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 111
Inhibition of GSK-3 Signalling Enhances Sensitivity of Non-Promyelocitic Acute Myeloid Leukemia (AML) Cell to Chemotherapy 109
A study of the crosstalk between CD30 and CXCR4 108
Autoimmune complications are frequent in splenic and nodal marginal zone lymphomas 107
TP53 mutations in adult acute lymphoblastic leukemia (ALL) are relatively frequent in molecularly negative case of both B- and T-lineage and correlate with poor response to induction therapy 107
Role of Wnt/β-Catenin Signalling in Acute Myeloid Leukemia (AML) Cell Response to Chemotherapy 105
Inhibition of Notch signalling overcomes bone marrow stromal-mediated anti-apoptotic and chemoresistance effects in AML. 103
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia and may provide prognostic informations 103
CXCL12 and [N33A]CXCL12 in 5637 and HeLa Cells: Regulating HER1 Phosphorylation via Calmodulin/Calcineurin 103
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis 102
The impact of a 7-day prednisone (PDN) pretreatment in adult (less than 60y) acute lymphoblastic leukemia (ALL) therapy: results of LAL2000 vs LAL0496. 102
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 101
The Sesquiterpene Oil {alpha}-Bisabolol Induces Apoptosis of B-Chronic Lymphocytic Leukemia Primary Cells 100
Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells 100
Rational of targeting WNT/beta-catenin signaling in acute myeloid leukemia (AML) 99
ALK-positive anaplastic large cell lymphoma with PAX-5 expression: report of a case 98
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis 96
Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis. 94
Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. 92
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 92
A preliminary experience with the HyperCHiDAM Verona intensive chemotherapy regimen in heavily pretreated refractory Hodgkin's lymphoma 90
High levels of tumor load reduction after intensive chemotherapy favorably affect the prognosis of BCR/ABL+ ALL adult patients receiving Imatinib Mesylate alone as a post-consolidation treatment according to the Italian GIMEMA LAL 0201/A protocol 89
Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases 89
Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis 88
Sesquiterpene α-bisabolol, which binds to Bid in lipid rafts, induces apoptosis in BCR/ABL+ cell lines through membrane depolarization. 88
Unexpected subacute leucoencephalopathy following intrathecal methotrexate and cytarabine administration in a patient homozygous for MTHFR 677C→T polymorphism. 86
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 86
Systemic mastocytosis: a muldisciplinary approach (Review) [Lamastocitosi sistemica: Un approccio multidiscliplinare] 85
Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels 85
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 84
Back to life – Living, treating, managing myelofibrosis: the burden of illness for patients and their families 83
BCR-ABL mutations in chronic myeloid leukemia (CML) patients (pts) with failure and warning to first- and second-lline tyrosine kinase inhibitor (TKI) therapy: what is the advantage of Next-Generation Sequencing (NGS) over conventional sequencing? 83
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients 83
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis 82
The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis 82
Plasmacytoid dendritic cell leukemia: a rapidly evolving disease presenting with skin lesions sensitive to radiotherapy plus hyperthermia. 81
Short-term, intensive chemotherapy regimen is equally effective in Burkitt lymphoma (BL) and in the novel WHO 2008 entity “B-cell lymphoma intermediate between DLBCL and BL". 81
A simple score predicts clonal mast cell disorders in patients with systemic reactions to Hymenoptera venom without skin lesions 81
In Chronic Myeloid Leukemia Patients on 2nd-Line Tyrosine Kinase Inhibitor Therapy, Deep Sequencing at the Time of Warning May Allow Sensitive Detection of Emerging BCR-ABL1 Mutants 80
Mitochondrial-Mediated Apoptosis by the Sesquiterpene Oil {alpha}-Bisabolol and Its Synergism with Imatinib and Nilotinib In BCR-ABL+ Cells. 79
High incidence of autoimmune complications in 82 patients with non-MALT marginal zone lymphomas. 78
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 78
Molecular “warning” CML patients: a retrospective study of Gruppo Triveneto LMC. 77
Serum tryptase levels differently change over time in indolent systemic mastocytosis with or without skin lesions. 77
Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis 77
The Plant-Derived Agent {alpha}-Bisabolol Induces Apoptosis of Leukemic Blasts Ex Vivo. 76
Improved detection of the C-KIT D816V mutation using allele-specific arms real time PCR assay allows a finer recognition of patients with indolent systemic mastocytosis. 76
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 76
CD66b-CD64dimCD115- cells in the human bone marrow represent neutrophil-committed progenitors 76
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 75
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 75
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis 75
Inhibition of Notch signaling enhances chemosensitivity in B cell precursor acute lymphoblastic leukemia 74
Skeletal implications of isolated bone marrow mastocytosis (reply): Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis (reply) 73
Bone Disease in Mastocytosis 73
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia 73
PBX/E2A transcript positive B-lymphoblastic leukemia (B-ALL) presenting with bilateral renal and myocardial involvement: a case report. 72
Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis 72
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 71
Blastic plasmacytoid dendritic cell leukemia: preliminary results of a retrospective italian multicentric study. 71
Ultra-deep sequencing (UDS) allows more sensitive detection of the D816V and other KIT gene mutations in systemic mastocytosis 71
EUTOS Score Identifies Cases with Poor Outcome in Patients with Early Chronic Phase Chronic Myeloid Leukemia, Though Not Predictive for Optimal Response to Imatinib 70
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 69
Characterization of a new B-ALL cell line with constitutional defect of the Notch signaling pathway 69
Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. 66
null 66
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 66
TCL1A expression in marginal zone lymphoma: a clinico-pathological evaluation in paired spleen and bone marrow samples 64
How patients perceive a switch from imatinib to nilotinib: results of a patient-centered analysis 64
Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis 64
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 64
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 63
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 60
Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association 59
Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements 59
Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia 59
Mast Cell Disorders In Drug Hypersensitivity 58
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia 57
EUTOS Score Predicts Optimal Response To Imatinib According To The Revised ELN Recommendations Better Than Sokal Score: A Study From The “Gruppo Triveneto LMC” 56
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 56
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 56
Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia 56
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk CML patients with favourable response to imatinib front-line. 55
Modified HyperCVAD and rituximab for the treatment of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. 55
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 55
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 54
Combination of EUTOS score and 3-months BCR-ABL transcript level identifies a distinct subgroup of ECP-CML patients with high risk of non optimal response and imatinib discontinuation. 53
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 53
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 53
Totale 8.365
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.425
article - articoli 26.253
book - libri 0
conference - conferenze 14.929
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 243
Totale 82.850
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.073 0 65 8 44 95 143 95 47 89 188 152 147
2020/20211.232 121 218 63 134 218 108 22 22 50 20 162 94
2021/20221.382 106 374 36 141 109 56 24 73 72 40 78 273
2022/20232.712 191 265 266 471 211 711 33 154 297 26 46 41
2023/20241.605 74 130 90 161 178 197 63 111 27 87 381 106
2024/2025335 189 146 0 0 0 0 0 0 0 0 0 0
Totale 11.271